Recon: Recursion to buy Exscientia for $688M; FDA approves Citius rare blood cancer treatment
ReconMichael Mezher
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States